Published: 6 March 2015
Author(s): Jaroslav A. Hubacek, Vera Adamkova, Petra Hruba, Richard Ceska, Michal Vrablik
Section: Letter to the Editor

Statins are the most common drugs used in both primary and secondary cardiovascular prevention. They lower plasma cholesterol levels by inhibiting the key enzyme of cholesterol synthesis, 3-hydroxy 3-methylglutaryl coenzyme A reductase. Statins have positive pleiotropic effects on many other risk factors of CVD, resulting in global reduction of cardiovascular risk. However, significant inter-individual differences in statin tolerability exist, and it is likely that they derive from a significant genetic background [1].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.